Skip to main content

Table 3 Treatment decision, duration, and outcome in both HCV patients post chemotherapy (cases) and HCV patients without cancer (controls)

From: Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience

  Groups of HCV patients Total
N (%)
171
p-value
Post chemotherapy
N (%)
83
Without cancer
N (%)
88
Treatment decision IFN/SOF/RBV 12 (14.5%) 5 (5.7%) 17 (9.9%)  
PAR/OMP/RBV 1 (1.2%) 1 (1.1%) 2 (1.2%)  
SOF/DAC 18 (21.7%) 44 (50%) 62 (36.3%)  
SOF/DAC/RBV 16 (19.3%) 20 (22.7%) 36 (21.1%)  
SOF/PAR/OMP/RBV 1 (1.2%) 0 (0%) 1 (0.6%)  
SOF/RBV 23 (27.7%) 18 (20.5%) 41 (24%)  
SOF/SIM 12 (14.5%) 0 (0%) 12 (7%)  
Treatment duration 12 weeks 55 (66.3%) 58 (65.9%) 113 (66.1%) 0.961
24 weeks 28 (33.7%) 30 (34.1 %) 58 (33.9%)  
Treatment outcome SVR 83 (100%) 86 (97.7%) 169 (98.9%) 0.497
Non SVR 0 (0%) 2 (2.3%) 2 (1.2%)  
SVR 83 (100%) 86 (97.7%) 169 (98.9%) 0.385
Relapser 0 (0%) 1 (1.1%) 1 (0.6%)
DC 0 (0%) 1 (1.1%) 1 (0.6%)
  1. SOF Sofosbuvir, RBV Ribavirin, INF Interferon, SIM Simeprevir, DAC Daclatasvir, PAR/OMP Paritaprevir/ombitasvir, DC Discontinue